BB Biotech's Koller: M&A could accelerate as soon as the political clouds shift

Daniel Koller, BB Biotech's head of investment, discusses sector growth, innovation and the attractive valuations of fast-growing companies.

Partner insight At the beginning of 2016, biotech equities were unable to withstand the downward pressure that put financial markets around the globe into bear territory. More recently, movements in the US to repeal and replace the Affordable Care Act have led to some short-term volatility. Yet this has not blunted the overall positive uptrend in the broad healthcare equity markets. Given that drug development programmes are lengthy and clinical setbacks common, how should investors approach this environment? Over the last five to ten years, we have seen compelling returns, bu...